Issue link: https://www.e-digitaleditions.com/i/1532011
News about companies that support development of orally inhaled and nasal drug products (OINDPs), including regulatory approvals, new partnerships, new products and services, and results of clinical studies. Inhalation February 2025 9 INDUSTRY NEWS Orbia to increase production of HFA152a RUNCORN, UNITED KING- DOM—Orbia Fluor & Energy Materials announced its readi- ness to advance construction of a larger- scale medical propel- lant purification plant, noting this marks a critical milestone in the metered dose inhaler (MDI) industry's transition to low global warming potential (GWP) inhal- ers. Once operational, the plant will significantly expand produc- tion capacity for Zephex ® 152a (HFA 152a) to meet high-volume needs. e plant will be built at Orbia Fluor & Energy Materials' existing Rocksavage site in Run- corn, UK. Pre-construction for the new facility is underway, with a goal of mid-2026 for capacity readiness. "For several years there has been an increased drive both internally and by our custom- ers to together reduce the carbon footprint associated with the use of pMDIs," said Markus Laub- scher, General Manager of the Orbia Fluor & Energy Materi- als Pharma business unit. "Today marks an exciting step forward in scaling production of our sustain- able medical propellant. With this larger-scale facility, we will enable our customers to transition faster." Intertek to partner with CrystecPharma CAMBRIDGE, UNITED K I N G D O M — I n t e r t e k a n - nounced a partnership with Crys- tecPharma, a crystal and particle engineering company, to advance formulation science and accel- erate development timelines for dry powder inhalers (DPIs). e companies will combine Inter- tek's GMP manufacturing and analytics expertise with Crystec- Pharma's proprietary modified su- percritical anti-solvent (mSAS ® ) drug formulation technology to provide a "fast to clinic" platform to support pharmaceutical clients with rapid DPI development, from initial formulation concept to GMP clinical manufacturing, in less than half the time typically required. A news release noted the highly agile, rapid framework will allow clients aiming to formulate small or large (biologics) mole- cules, or to repurpose existing ac- tive pharmaceutical ingredients, to benefit from technology that en- ables new forms of molecules to be crystallized and novel particles to be manufactured in ways that greatly enhance their therapeutic performance. "is unique plat- form will enable highly effective, stable and safe DPI medicines to be developed and brought to mar- ket in a fraction of the time previ- ously possible," said Chris Vernall, Intertek Commercial Director. Merxin Ltd and OECHSLERhealth launch new venture KING'S LYNN, NORFOLK, UNITED KINGDOM AND ANSBACH, BAYERN, GER- MANY—Merxin, Ltd., a de- signer and supplier of inhalers and OECHSLERhealth, a con- tract manufacturing organization (CMO), announced a partnership to establish e SMI PowerHouse. e collaboration, which began in 2018, aims to streamline and widen access to soft mist inhal- ers (SMIs) and accelerate the path to market for drug developers. By leveraging OECHSLERhealth's manufacturing and assembly ex- pertise and Merxin Ltd's propri- etary MRX004 SMI design and market access, e SMI Power- House intends to provide reduced time to market, enhanced reliabil- ity, increased access to drug deliv- ery and cost effectiveness. "is partnership with OECHSLER- health brings to life our vision for e SMI Powerhouse, enabling quicker and more reliable access to market- ready SMIs while main- taining our focus on patient care and environmental stewardship," said Philippe Rogueda, Chief Business Officer of Merxin Ltd. continued on page 33 • Centrally manage all projects, apparatuses, and testing protocols. • Create re-usable workflow templates for all testing, analytics, and reporting. • Supports all USP / Ph. Eur. apparatuses and configurations. Fully supports 21 CFR 11 compliance. • Full bi-directional CDS automation for ChemStation, Chromeleon ™ , and Empower ™ . • Companion module for formulation and device design R&D. Fusion Inhaler Testing Software ™ The Only Fully Automated Software Solution for Oral and Nasally Inhaled Drug Product R&D and QC www.smatrix.com sales@smatrix.com